| | | | | | | | | | | | | | | | |
| | |
 | Issue Date FY: 2023 ( Subtotal = -$36,316 ) |
| | 2023 | 2021 | TAMBO, INC. | 665 3RD ST | SAN FRANCISCO | CA | 94107-1953 | SAN FRANCISCO | USA | R44GM130240 | Material-guided delivery and local activation of bioorthogonal prodrugs | 000 | 3 | NIH | 9/28/2023 | -$36,316 |
|
| Issue Date FY: 2022 ( Subtotal = $300,224 ) |
| | 2022 | 2022 | TAMBO INC | 665 3RD ST | SAN FRANCISCO | CA | 94107-1953 | SAN FRANCISCO | USA | R43TR004026 | Generalizable Protodrug Characteristics for In Vivo Drug Release using the Click Activated Protodrugs (CAP) Platform | 000 | 1 | NIH | 8/17/2022 | $300,224 |
| | 2022 | 2022 | TAMBO INC | 665 3RD ST | SAN FRANCISCO | CA | 94107-1953 | SAN FRANCISCO | USA | R43TR004026 | Generalizable Protodrug Characteristics for In Vivo Drug Release using the Click Activated Protodrugs (CAP) Platform | 001 | 1 | NIH | 9/14/2022 | $0 |
| | 2022 | 2018 | TAMBO INC | 665 3RD ST | SAN FRANCISCO | CA | 94107-1953 | SAN FRANCISCO | USA | R43HD093495 | Material guided drug delivery for pediatric tumors using an implantable biomaterial and bio-orthogonal chemistry | 000 | 1 | NIH | 12/22/2021 | $0 |
|
| Issue Date FY: 2021 ( Subtotal = $577,898 ) |
| | 2021 | 2021 | TAMBO, INC. | 665 3RD ST SUITE 250 | SAN FRANCISCO | CA | 94107-1953 | SAN FRANCISCO | USA | R44GM130240 | Material-guided delivery and local activation of bioorthogonal prodrugs | 003 | 3 | NIH | 9/9/2021 | $577,898 |
| | 2021 | 2020 | TAMBO, INC. | 665 3RD ST SUITE 250 | SAN FRANCISCO | CA | 94107-1953 | SAN FRANCISCO | USA | R44GM130240 | Material-guided delivery and local activation of bioorthogonal prodrugs | 002 | 2 | NIH | 4/29/2021 | $0 |
| | 2021 | 2020 | TAMBO, INC. | 665 3RD ST SUITE 250 | SAN FRANCISCO | CA | 94107-1953 | SAN FRANCISCO | USA | R44GM130240 | Material-guided delivery and local activation of bioorthogonal prodrugs | 001 | 2 | NIH | 2/15/2021 | $0 |
| | 2021 | 2019 | TAMBO, INC. | 665 3RD ST SUITE 250 | SAN FRANCISCO | CA | 94107-1953 | SAN FRANCISCO | USA | R44GM130240 | Material-guided delivery and local activation of bioorthogonal prodrugs | 000 | 1 | NIH | 2/3/2021 | $0 |
| | 2021 | 2018 | TAMBO, INC. | 665 3RD ST SUITE 250 | SAN FRANCISCO | CA | 94107-1953 | SAN FRANCISCO | USA | R43HD093495 | Material guided drug delivery for pediatric tumors using an implantable biomaterial and bio-orthogonal chemistry | 000 | 1 | NIH | 2/24/2021 | $0 |
|
| Issue Date FY: 2020 ( Subtotal = $860,523 ) |
| | 2020 | 2020 | TAMBO, INC. | 665 3RD ST SUITE 250 | SAN FRANCISCO | CA | 94107-1953 | SAN FRANCISCO | USA | R44GM130240 | Material-guided delivery and local activation of bioorthogonal prodrugs | 000 | 2 | NIH | 8/14/2020 | $910,710 |
| | 2020 | 2018 | TAMBO, INC. | 665 3RD ST SUITE 250 | SAN FRANCISCO | CA | 94107-1953 | SAN FRANCISCO | USA | R43CA224561 | Material guided drug delivery for pigmented villonodular synovitis using an implantable biomaterial and bio-orthogonal chemistry | 000 | 1 | NIH | 8/26/2020 | -$50,187 |
| | 2020 | 2018 | TAMBO, INC. | 665 3RD ST SUITE 250 | SAN FRANCISCO | CA | 94107-1953 | SAN FRANCISCO | USA | R43HD093495 | Material guided drug delivery for pediatric tumors using an implantable biomaterial and bio-orthogonal chemistry | 000 | 1 | NIH | 7/8/2020 | $0 |
|
| Issue Date FY: 2019 ( Subtotal = $216,910 ) |
| | 2019 | 2019 | SHASQI, INC | 665 3RD ST SUITE 250 | SAN FRANCISCO | CA | 94107-1953 | SAN FRANCISCO | USA | R44GM130240 | Material-guided delivery and local activation of bioorthogonal prodrugs | 000 | 1 | NIH | 4/2/2019 | $216,910 |
|
| Issue Date FY: 2018 ( Subtotal = $595,271 ) |
| | 2018 | 2018 | SHASQI, INC | 665 3RD ST SUITE 250 | SAN FRANCISCO | CA | 94107-1953 | SAN FRANCISCO | USA | R43HD093495 | Material guided drug delivery for pediatric tumors using an implantable biomaterial and bio-orthogonal chemistry | 000 | 1 | NIH | 7/26/2018 | $299,877 |
| | 2018 | 2018 | SHASQI, INC | 665 3RD ST SUITE 250 | SAN FRANCISCO | CA | 94107-1953 | SAN FRANCISCO | USA | R43CA224561 | Material guided drug delivery for pigmented villonodular synovitis using an implantable biomaterial and bio-orthogonal chemistry | 000 | 1 | NIH | 7/20/2018 | $295,394 |
| | 2018 | 2016 | SHASQI, INC | 665 3RD ST SUITE 250 | SAN FRANCISCO | CA | 94107-1953 | SAN FRANCISCO | USA | R43GM119864 | Using implantable biomaterial and bio-orthogonal chemistry to guide delivery of antibiotics | 000 | 1 | NIH | 6/19/2018 | $0 |
|
| Issue Date FY: 2016 ( Subtotal = $224,984 ) |
| | 2016 | 2016 | SHASQI, INC | 136 CHESHAM AVE | SAN CARLOS | CA | 94070-2802 | SAN MATEO | USA | R43GM119864 | Using implantable biomaterial and bio-orthogonal chemistry to guide delivery of antibiotics | 000 | 1 | NIH | 8/15/2016 | $224,984 |
|
|
